Last reviewed · How we verify
BT086
BT086 is a monoclonal antibody targeting CD19.
BT086 is a monoclonal antibody targeting CD19. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma.
At a glance
| Generic name | BT086 |
|---|---|
| Sponsor | Biotest |
| Drug class | Monoclonal antibody |
| Target | CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to CD19 on the surface of B cells, marking them for destruction by the immune system. This leads to a reduction in B cell count and activity, which can help to treat certain types of cancer.
Approved indications
- Relapsed or refractory B-cell non-Hodgkin lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Leukopenia
- Infections
- Infusion reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BT086 CI brief — competitive landscape report
- BT086 updates RSS · CI watch RSS
- Biotest portfolio CI